(Reuters) – AstraZeneca said on Monday it had finalised plans to divest its Crohn’s disease drug Entocort by selling U.S. rights to the medicine to Perrigo (PRGO.N) for $380 million.
The move is part of an “externalization” drive by the British drugmaker, which is selling non-core products to help it fill a short-term revenue gap caused by older products going off product, while investing in a pipeline of new medicines.
Entocort had U.S. sales of $89 million in the first nine months of 2015.
The deal, which is expected to complete by the end of 2015, follows AstraZeneca’s sale of rights to Entocort outside the United States in July to Tillotts Pharma, part of the Zeria Group.
AstraZeneca said its earnings per share outlook for the year, which was upgraded at third-quarter results earlier this month, would not change as a result of the Perrigo transaction.
(Reporting by Ben Hirschler; editing by Jason Neely)
The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones.
Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.
A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.
